Description
Talimogene laherparepvec[a] is a biopharmaceutical drug to treat melanoma that cannot be operated on; it is injected directly into a subset of lesions which generates a systemic immune response against the patient’s cancer.
The drug was created and initially developed by BioVex, Inc. and was continued by Amgen, which acquired BioVex in 2011. It was the first oncolytic immunotherapy approved globally; it was approved in the US in October 2015 and approved in Europe in December 2015.
Get Access to IMLYGIC (talimogene laherparepvec) In India
Medvitaz Pharma is equipped to facilitate the distribution of IMLYGIC (talimogene laherparepvec) (prescription medications) worldwide and throughout India upon completion of necessary legal procedures, if applicable.
To inquire about the price of either the branded medication “IMLYGIC (talimogene laherparepvec)” or the generic version “talimogene laherparepvec” for personal use under patient-specific treatment in various cities including Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, and others in India, please fill out the request form. Upon receiving your request and assessing the delivery process, we will provide you with an estimated price for the medication within 24 hours.
For any inquiries or assistance, please reach out to our Patient Support Team. We are available to assist you from Monday to Friday, between 9:00 and 19:00 IST. You can contact us via email at [email protected], toll-free at +91 8750295029, or through WhatsApp at +91-8750295029.
We can help facilitate the supply of IMLYGIC (talimogene laherparepvec) through legal channels.